Beginning in mid-February 2008, the 1997-2007 online version of the Science Watch® newsletter, ESI-Topics.com, and in-cites.com, will all be featured together on the redesigned ScienceWatch.com. All previous content from the three sites will be permanently archived, and remain accessible from any existing bookmarks to the archived pages. No new content will be added to this site. Updates and new content (updated biweekly) are available at ScienceWatch.com now.

Fast Moving Fronts Comments
Return to menu of Fast Moving Fronts

ESI Special Topics, September 2005
Citing URL: http://www.esi-topics.com/fmf/2005/september05-JonJureidini.html

From •>>September 2005

Jon Jureidini answers a few questions about this month's fast moving front in the field of Psychiatry/Psychology.

Field: Psychiatry/Psychology
Article: Efficacy and safety of antidepressants for children and adolescents
Authors: Jureidini, JN;Doecke, CJ;Mansfield, PR;Haby, MM;Menkes, DB;Tonkin, AL
Journal: BRIT MED J, 328: (7444) 879-883, APR 10 2004
Addresses:
Womens & Childrens Hosp, Dept Psychol Med, Adelaide, SA 5006, Australia.
Womens & Childrens Hosp, Dept Psychol Med, Adelaide, SA 5006, Australia.
Univ S Australia, Qual Use Med & Pharm Res Ctr, Adelaide, SA 5000, Australia.
Univ S Australia, Dept Gen Practice, Adelaide, SA 5005, Australia.
Univ Adelaide, Dept Clin & Expt Pharmacol, Adelaide, SA 5005, Australia.
Dept Human Serv, Hlth Surveillance & Evaluat Sect, Melbourne, Vic 3000, Australia.
Univ Wales, Acad Unit, Wrexham LL13 7YP, Wales.


   Why do you think your paper is highly cited?

It is a timely contribution to the debate on antidepressants in children.

   Does it describe a new discovery or new methodology that's useful to others?

It’s useful to others to remember that a paper’s summary and conclusions might be flawed, sometimes apparently deliberately.

   Could you summarize the significance of your paper in layman's terms?

Investigators’ conclusions on the efficacy of newer antidepressants in childhood depression have exaggerated their benefits, and downplayed adverse effects. Improvement in control groups is strong; additional benefit from drugs is of doubtful clinical significance. Antidepressant drugs cannot confidently be recommended as a treatment option for childhood depression.

   How did you become involved in this research?

I was worried by misleading papers.End

Jon Jureidini Ph.D., M.B.B.S., FRANZCP
Clinical Senior Lecturer
Department of Psychiatry
University of Adelaide
Adelaide, Australia
and
Senior Research Fellow
Department of Philosophy
Flinders University of South Australia
Adelaide, Australia
and
Head, Department of Psychological Medicine
Women's and Children's Hospital
Adelaide, Australia

Return to Fast Moving Fronts | Return to Special Topics main menu
 

ESI Special Topics, September 2005
Citing URL: http://www.esi-topics.com/fmf/2005/september05-JonJureidini.html
ScienceWatch.com - Tracking Trends and Perfomance in Basic Research
Go to the new ScienceWatch.com
Write to the Webmaster with questions/comments. Terms of Usage.
The Research Services Group of Thomson Scientific |
(c) 2008 The Thomson Corporation.